autogene cevumeran + atezolizumab

Autogene cevumeran + atezolizumab is an investigational combination therapy under clinical development for the treatment of advanced and resected solid tumors, including pancreatic ductal adenocarcinoma (PDAC). **Autogene cevumeran** is a uridine messenger RNA (mRNA) lipoplex-based, individualized neoantigen-specific immunotherapy. It is manufactured for each patient using the mutational landscape of the patient's tumor to encode up to 20 tumor-specific neoantigens, aiming to stimulate robust polyclonal T cell responses (both CD4+ and CD8+) against cancer mutations. **Atezolizumab** is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor, preventing the suppression of the immune response by tumor cells. The combination is designed to potentiate antitumor immunity by both generating new anti-cancer T cell responses (via individualized vaccination) and sustaining/enhancing these responses (by blocking PD-L1-mediated immune evasion). The combination is being tested as adjuvant therapy and for advanced/metastatic solid tumors, with published phase 1 and ongoing phase 2 trials, particularly in resected pancreatic cancer.

Brand names

Tecentriq (for atezolizumab)

Other names

autogene cevumeran (for RO7198457)personalized cancer vaccine RO7198457